Belgium's Multiplicom Wins $250K to Develop Non-Invasive Multiplex PCR-based Fetal Aneuploidy Dx | GenomeWeb

Belgian molecular diagnostics firm Multiplicom said this week that it has been awarded €200,000 ($250,000) from the Flemish agency for Innovation by Science and Technology to develop a blood-based non-invasive molecular diagnostic test for fetal aneuploidy.

The test would use the same multiplexed endpoint PCR- and sequencing-based workflow as the other tests in Multiplicom's portfolio, including research-use-only diagnostic kits for breast cancer, colon cancer, and cystic fibrosis.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

This Week in Science: New research into the emergence of infectious diseases, and scientists report on proteins involved in melanoma.

The hashtag #stupidcommonnames is gaining fans among scientists who find the common names of some animals and plants dumb.

Fed up with budget slashes, job cuts, and muzzling mandates, researchers in Canada are making science a campaign issue in the upcoming elections.

A former NIH program officer says the Internet has blasted open the door for scientific publications more interested in dollars than quality research.